Abbott Gmbh & Co Kg

Abbott Laboratories Corporation

Abbvie Inc.

Abb Vie Deutschland Gmbh & Co. Kg

Alexander Robert Duncan

Boris Labkovsky

Jochen G Salfeld

Michael White

Michael Roguska

Geertruida Machteld Veldman

Zehra Kaymakcalan

Paul Sakorafas

Nicholas W Warne

Subhashis Banerjee

Angela Widom

Thor Las Holtet

Daniel Edward Tracey

Elaine Joy Derbyshire

Sara Carmen

John Gawain Elvin

Michael Paskind

Stephen Smith

Sarah Leila Du Fou

Stuart Friedrich

Amy Venturini

Angela Myles

Angela Kantor

Richard W Dixon

John A Mankovich

Tariq Ghayer

Simon Mark Brocklehurst

Celia Patricia Shorrock

Julia Elizabeth Thompson

Simon Nicholas Lennard

Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Human antibodies that bind the P40 subunit of human IL-12 and methods for using the same

Methods of treatment using human antibodies that bind IL-12

Human antibodies that bind human interleukin-12

Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12 ) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Methods for inhibiting the activity of the P40 subunit of human IL-12

Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.

Antibodies that bind IL-18 and methods of inhibiting IL-18 activity

Human antibodies that bind human IL-12

Human antibodies that bind human IL-12 and methods for producing

Growing community of inventors

Cambridge, United Kingdom

Alexander Robert Duncan